Premium
Zinc supplementation prevents increases in prevalence of hypertension among HIV infected adults in Miami
Author(s) -
Lima Claudia,
Campa Adriana,
Sales Sabrina,
Stewart Tiffanie,
Garces Luis,
Baum Marianna K
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.718.7
Subject(s) - medicine , placebo , blood pressure , human immunodeficiency virus (hiv) , population , analysis of variance , clinical trial , post hoc analysis , placebo group , epidemiology , demography , immunology , environmental health , alternative medicine , pathology , sociology
Objective HIV is a risk factor for hypertension (HTN). This study examines the prevalence of HTN in a clinical trial of HIV+ adults receiving zinc (12 mg for women and 15 mg for men) or placebo over 18 months. Methods After consenting 231 HIV+ adults, physical examinations were done. HTN was defined as having diagnosed HTN, blood pressure >140/90 or receiving treatment for HTN at baseline, 6, 12, and 18 months. Descriptive statistics, ANOVA (controlled for age and ART), and Post‐Hoc tests were performed. Results Mean age was 42.7±7.0 years. The prevalence of HTN was 48.9% (n=113; 82 women, 31 men), significantly increasing over 18 months by 12±3.2%. There were significant interactions between time, treatment and gender in modifying HTN (p=0.015). When compared to women supplemented with zinc, women on placebo had a significant and sustained increase in the prevalence of HTN (5.1% vs. 3.28%, p=0.016) by 18 months. Men on placebo, as compared to those on zinc, had significant increase in prevalence of HTN at 6 months (14.8 vs. 1.9%, p=0.037) with no differences afterwards. Conclusions The prevalence of HTN among HIV+ adults in Miami is almost twice that of the general population (48.9% vs. 25.5%) of similar age. Zinc supplementation compared to placebo, prevented increases in HTN in women and to a lesser extent in men. Further studies are needed to elucidate the mechanisms for zinc action on HTN. Supported by NIDA